Related Experiment Video
Updated: Jun 16, 2026
07:36
Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
[Hypermethioninemia in the preterm newborn. Predisposing factors]
O López-Suárez1, M L Couce Pico, A Pérez-Muñuzuri
1Departamento de Pediatría, Hospital Clínico Universitario de Santiago, Santiago de Compostela, España.
Anales De Pediatria (Barcelona, Spain : 2003)
|February 2, 2010
Summary
High methionine intake in preterm infants fed special formulas is linked to transient isolated hypermethioninemia. This condition, however, did not correlate with neurodevelopmental outcomes at six months.
Area of Science:
- Biochemistry
- Neonatology
- Neuroscience
Context:
- Excess methionine intake can lead to central nervous system disorders in infants.
- Preterm infants are particularly vulnerable to metabolic imbalances.
- Neonatal screening identifies metabolic conditions early.
Purpose:
- To investigate the relationship between methionine intake and hypermethioninemia in preterm infants.
- To assess the impact of isolated hypermethioninemia on neurodevelopment.
- To analyze the duration of elevated methionine levels in relation to formula feeding.
Summary:
- A study of 187 preterm infants found 16 with isolated hypermethioninemia.
- Methionine-enriched formulas were associated with increased hypermethioninemia cases (62.6%).
- A significant correlation was observed between formula duration and methionine level normalization (R 0.791, p=0.000).
Impact:
- Highlights the critical role of amino acid supplementation, specifically methionine, in preterm infant formulas.
- Suggests careful monitoring of methionine levels in infants receiving specialized nutritional support.
- Informs clinical practice regarding formula composition and potential neurological development impacts.
More Related Videos
Related Concept Videos
01:20Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:20Pathophysiology of Diabetes
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:28Development of the Oral Microbiota
The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...